首页 | 本学科首页   官方微博 | 高级检索  
检索        

叉头框转录蛋白1在弥漫性大B细胞淋巴瘤中的表达及预后意义
引用本文:胡成如,王靖华,耿怀成,孙茜,陈龙邦.叉头框转录蛋白1在弥漫性大B细胞淋巴瘤中的表达及预后意义[J].临床肿瘤学杂志,2012,17(4):339-342.
作者姓名:胡成如  王靖华  耿怀成  孙茜  陈龙邦
作者单位:210002 南京 南京大学医学院临床学院 南京军区南京总医院肿瘤内科
摘    要:目的 探讨叉头框转录蛋白1(FOXP1)在弥漫性大B细胞淋巴瘤(DLBCL)中的表达及其与DLBCL临床病理特征和预后的关系。方法 用免疫组织化学En Vision法检测85例DLBCL组织中FOXP1蛋白的表达情况,并分析FOXP1与临床病理特征及预后的关系。结果 85例DLBCL组织中FOXP1的阳性表达率为71.8%(61/85),FOXP1表达与年龄、PS评分、乳酸脱氢酶(LDH)水平、国际预后指数评分、病理类型密切相关(P<0.05)。在生发中心型(GCB)DLBCL中FOXP1阳性和阴性表达者的无病生存期(PFS)为13个月和44个月(P=0.002),总生存期(OS)为28个月和50个月(P=0.003);而在非生发中心型(non-GCB)中FOXP1表达与生存预后无关(P>0.05)。单因素分析显示分期、LDH水平、有无B症状以及FOXP1表达与DLBCL患者的PFS和OS均相关(P<0.05),Cox多因素回归分析显示分期(95%CI:1.410~4.415,P=0.02)和FOXP1表达(95%CI:0.143~0.734,P=0.007)是PFS的独立预测因素。 结论 FOXP1蛋白有可能是DLBCL的一个重要的预后指标,尤其在GCB型DLBCL中FOXP1蛋白阳性表达提示预后不佳。

关 键 词:叉头框转录蛋白1  弥漫性大B细胞淋巴瘤  预后  免疫组织化学
收稿时间:2011-11-10
修稿时间:2011-12-21

Expression and clinical significance of FOXP1 in diffuse large B-cell lymphoma
HU Cheng-ru , WANG Jing-hua , GENG Huai-cheng , SUN Qian , CHENG Long-bang.Expression and clinical significance of FOXP1 in diffuse large B-cell lymphoma[J].Chinese Clinical Oncology,2012,17(4):339-342.
Authors:HU Cheng-ru  WANG Jing-hua  GENG Huai-cheng  SUN Qian  CHENG Long-bang
Institution:HU Cheng-ru,WANG Jing-hua,GENG Huai-cheng,SUN Qian,CHENG Long-bang.Department of Oncology,Nanjing General Hospital of Nanjing Military Command,Clinical College of Medical School of Nanjing University,Nanjing 210002,China
Abstract:Objective To investigate the clinical and prognostic significance of forkhead box protein1(FOXP1) expression in diffuse large B-cell lymphoma(DLBCL).Methods Tumor tissues from 85 DLBCL were analyzed for FOXP1 protein expression using immunohistochemistry and the correlation with clinicopathologic features and prognosis.Results Of all the 85 patients,61(71.8%) showed FOXP1 positive expression,and the expression rate of FOXP1 protein in DLBCL had relation with ages,PS score,LDH,IPI and pathologic types.FOXP1 positive expression had significantly worse progress free survival(PFS) compared to FOXP1 negative expression(13 months vs.44 months,P=0.002) and overall survival(OS)(28 months vs.50 months,P=0.003) in the GCB phenotype.However,FOXP1 in non-GCB phenotype was not related to prognosis.Univariate analysis identified that FOXP1,stage,LDH and B symptoms were prognostic factors of PFS and OS.Multivariate Cox regression analysis identified that stage(95%CI:1.410-4.415,P=0.002) and FOXP1 expression(95%CI:0.143-0.734,P=0.007) were independent prognostic factors of PFS,but not OS in DLBCL.Conclusion FOXP1 expression in DLBCL tissues may be a valuable biomarker for predicting the survival of DLBCL patients,especially in GCB phenotype.
Keywords:FOXP1  Diffuse large B-cell lymphoma  Prognosis  Immunohistochemistry
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《临床肿瘤学杂志》浏览原始摘要信息
点击此处可从《临床肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号